[go: up one dir, main page]

AU2001284354A1 - Immunological adjuvant compounds, compositions, and methods of use thereof - Google Patents

Immunological adjuvant compounds, compositions, and methods of use thereof

Info

Publication number
AU2001284354A1
AU2001284354A1 AU2001284354A AU8435401A AU2001284354A1 AU 2001284354 A1 AU2001284354 A1 AU 2001284354A1 AU 2001284354 A AU2001284354 A AU 2001284354A AU 8435401 A AU8435401 A AU 8435401A AU 2001284354 A1 AU2001284354 A1 AU 2001284354A1
Authority
AU
Australia
Prior art keywords
methods
compositions
immunological adjuvant
adjuvant compounds
novel compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001284354A
Inventor
Lynn D Hawkins
Sally T. Ishizaka
Michael Lewis
Pamela Mcguiness
Jeffrey Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of AU2001284354A1 publication Critical patent/AU2001284354A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides novel compounds that function as immunological adjuvants when co-administered with antigens, including, antigens used as vaccines for any disease or condition amenable to vaccination. The invention also provides adjuvant formulations comprising the novel compounds of the invention and methods for immunizing humans and non-human animals.
AU2001284354A 2000-07-31 2001-07-27 Immunological adjuvant compounds, compositions, and methods of use thereof Abandoned AU2001284354A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22175200P 2000-07-31 2000-07-31
US60221752 2000-07-31
PCT/IB2001/001658 WO2002009752A2 (en) 2000-07-31 2001-07-27 Immunological adjuvant compounds

Publications (1)

Publication Number Publication Date
AU2001284354A1 true AU2001284354A1 (en) 2002-02-13

Family

ID=22829213

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001284354A Abandoned AU2001284354A1 (en) 2000-07-31 2001-07-27 Immunological adjuvant compounds, compositions, and methods of use thereof

Country Status (8)

Country Link
US (1) US6521776B2 (en)
EP (1) EP1307466B1 (en)
JP (1) JP4230765B2 (en)
AT (1) ATE310008T1 (en)
AU (1) AU2001284354A1 (en)
DE (1) DE60115051T2 (en)
TW (1) TWI305775B (en)
WO (1) WO2002009752A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
TW200523235A (en) * 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
WO2006116423A2 (en) 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
AU2006265986B2 (en) 2005-06-30 2012-02-23 Eisai R&D Management Co., Ltd Compounds for preparing immunological adjuvant
KR20080080087A (en) * 2005-09-30 2008-09-02 티티아이 엘뷰 가부시키가이샤 Transdermal Drug Delivery System, Apparatus and Method Using Novel Pharmaceutical Carrier
JP2009509634A (en) * 2005-09-30 2009-03-12 Ｔｔｉ・エルビュー株式会社 Functionalized microneedle transdermal drug delivery system, apparatus and method
KR20080066712A (en) * 2005-09-30 2008-07-16 티티아이 엘뷰 가부시키가이샤 Functionalized Microneedle Transdermal Drug Delivery System, Apparatus and Method
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation
MX2010006275A (en) * 2007-12-18 2010-06-23 Eisai R&D Man Co Ltd Reagents and methods for the beta-keto amide synthesis of a synthetic precursor to immunological adjuvant e6020.
WO2018070543A1 (en) * 2016-10-14 2018-04-19 株式会社ボナック Novel glycoside compound and production method therefor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2583892A (en) 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
EP0732936B1 (en) 1993-12-09 2000-03-29 Heinrich Exner Adjuvant for antigens, process for producing the same and its use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE19511276C2 (en) * 1995-03-27 1999-02-18 Immuno Ag Adjuvant based on colloidal iron compounds
US5834015A (en) 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
ATE471328T1 (en) 1999-02-01 2010-07-15 Eisai R&D Man Co Ltd COMPOUNDS WITH IMMUNOLOGICAL ADJUVANT EFFECT

Also Published As

Publication number Publication date
EP1307466A2 (en) 2003-05-07
JP2004505059A (en) 2004-02-19
US20020049314A1 (en) 2002-04-25
DE60115051D1 (en) 2005-12-22
EP1307466B1 (en) 2005-11-16
WO2002009752A3 (en) 2002-06-27
ATE310008T1 (en) 2005-12-15
US6521776B2 (en) 2003-02-18
TWI305775B (en) 2009-02-01
JP4230765B2 (en) 2009-02-25
WO2002009752A2 (en) 2002-02-07
DE60115051T2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
DK1147117T3 (en) Immunological adjuvant compounds
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
EP1326633A4 (en) COMPOSITION COMPRISING IMMUNOGENIC MICROPARTICLES
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
IS4518A (en) New vaccine formulation
PT1104306E (en) CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS
NO20015073D0 (en) vaccinations
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2005037190A3 (en) Multiplex vaccines
EP1594536A4 (en) Adjuvanted influenza vaccine
WO2002087494A3 (en) Novel vaccine
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
EA200800917A1 (en) ADJUVANTA FOR VACCINES
WO2004020585A3 (en) Use of escherichia coli heat labile toxin as an adjuvant in birds and poultry
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
WO2002085409A3 (en) Methods and compositions for inducing an immune response to an antigen
MXPA06010616A (en) Vaccine compositions which are obtained from streptomyces.